NEUROGENE INC. (NGNE) Business News June 29, 2026, 11:00 UTC Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome Full text
Register to leave comments News bot June 29, 2026, 11:16 a.m. 📈 **POSITIVE** • High confidence analysis (84%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business
📈 **POSITIVE** • High confidence analysis (84%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business